VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Ferris on the Updated Data from CheckMate-141 in Head and Neck Cancer

Robert Ferris, MD, PhD
Published: Thursday, Apr 19, 2018



Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the updated findings from the CheckMate-141 trial in head and neck cancer.

CheckMate-141 is investigating nivolumab (Opdivo) versus investigator’s choice in patients with recurrent of metastatic squamous cell carcinoma of the head and neck. The 2-year outcomes in the overall population and PD-L1 subgroups were presented during the 2018 AACR Annual Meeting.

Findings showed that nivolumab improved overall survival (OS) significantly versus investigator’s choice in the overall population. Median OS was 7.7 months (95% CI, 5.7-8.8) with nivolumab compared with 5.1 months (95% CI, 4.0-6.2) for investigator's choice of therapy (HR, 0.68; 95% CI, 0.54-0.86). The 2-year OS rate was 16.9% with nivolumab (95% CI, 12.4%-22.0%) versus 6% in the control arm (95% CI, 2.7%-11.3%). Additionally, the risk of death was reduced by 32% with the PD-1 inhibitor.


Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the updated findings from the CheckMate-141 trial in head and neck cancer.

CheckMate-141 is investigating nivolumab (Opdivo) versus investigator’s choice in patients with recurrent of metastatic squamous cell carcinoma of the head and neck. The 2-year outcomes in the overall population and PD-L1 subgroups were presented during the 2018 AACR Annual Meeting.

Findings showed that nivolumab improved overall survival (OS) significantly versus investigator’s choice in the overall population. Median OS was 7.7 months (95% CI, 5.7-8.8) with nivolumab compared with 5.1 months (95% CI, 4.0-6.2) for investigator's choice of therapy (HR, 0.68; 95% CI, 0.54-0.86). The 2-year OS rate was 16.9% with nivolumab (95% CI, 12.4%-22.0%) versus 6% in the control arm (95% CI, 2.7%-11.3%). Additionally, the risk of death was reduced by 32% with the PD-1 inhibitor.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x